Plain-English translation of NCT05832489 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This research study examines how methylphenidate affects brain activity in adults with attention deficit hyperactivity disorder (ADHD). Researchers will use two types of brain imaging — MRI and EEG — to see how the medication influences the brain's response to tasks requiring focus and attention. The study compares people with ADHD alone, people with ADHD-like attention problems related to mood disorders, and healthy adults without ADHD.
While methylphenidate is commonly prescribed for ADHD, scientists still don't fully understand exactly how it changes brain function. This trial aims to reveal those mechanisms so doctors can better tailor treatment and predict who will benefit most from this medication.
You likely qualify if…
You likely don't qualify if…
You will attend two imaging sessions about 2–4 weeks apart. At each session, you will take either the medication or a placebo, then undergo brain imaging (MRI for about 65 minutes) and EEG recording (about 40 minutes) while performing attention tasks on a computer. Before the imaging sessions, you will complete questionnaires and a 45-minute neuropsychological assessment. The entire study spans about 3 months from start to finish.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
France